Literature DB >> 22197810

Mdm2 is a novel activator of ApoCIII promoter which is antagonized by p53 and SHP inhibition.

Zhihong Yang1, Yuxia Zhang, Li Wang.   

Abstract

We examined the effect of Mdm2 on regulation of the ApoCIII promoter and its cross-talk with p53 and nuclear receptor SHP. Overexpression of Mdm2 markedly enhanced ApoCIII promoter activity by HNF4α. A direct association of Mdm2 protein with the HNF4α protein was observed by co-immunoprecipitation. Ectopic expression of p53 decreased HNF4α activation of the ApoCIII promoter and antagonized the effect of Mdm2. Co-expression of SHP further strengthened p53 inhibition and abolished Mdm2 activation of the ApoCIII promoter. Mdm2 inhibited p53-mediated enrichment of HNF4α to the ApoCIII promoter while simultaneously reducing p53 binding and increasing recruitment of SHP to the ApoCIII promoter. The results from this study implicate a potentially important function of Mdm2 in regulation of lipoprotein metabolism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22197810      PMCID： PMC3259241          DOI： 10.1016/j.bbrc.2011.12.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  14 in total

1.  Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity.

Authors:  Yutaka Maeda; Shawn D Seidel; Gang Wei; Xuan Liu; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2002-02

Review 2.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

3.  The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.

Authors:  Xiongbin Lu; Ou Ma; Thuy-Ai Nguyen; Stephen N Jones; Moshe Oren; Lawrence A Donehower
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

4.  HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma.

Authors:  Belén Lucas; Karen Grigo; Silke Erdmann; Jörn Lausen; Ludger Klein-Hitpass; Gerhart U Ryffel
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

5.  The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo.

Authors:  N V Guevara; H S Kim; E I Antonova; L Chan
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

6.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

7.  Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter.

Authors:  Wendy W Hwang-Verslues; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2007-09-20

8.  Identification of ANKRD11 as a p53 coactivator.

Authors:  Paul M Neilsen; Kelly M Cheney; Chia-Wei Li; J Don Chen; Jacqueline E Cawrse; Renée B Schulz; Jason A Powell; Raman Kumar; David F Callen
Journal:  J Cell Sci       Date:  2008-10-07       Impact factor: 5.285

9.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

Authors:  M Chen; J L Breslow; W Li; T Leff
Journal:  J Lipid Res       Date:  1994-11       Impact factor: 5.922

10.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Authors:  B Staels; N Vu-Dac; V A Kosykh; R Saladin; J C Fruchart; J Dallongeville; J Auwerx
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808
View more
  7 in total

1.  Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS.

Authors:  Cui Li; Guo Xia; Zhang Jianqing; Yang Mei; Bai Ge; Zhang Li
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

Review 2.  Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Authors:  Swetha Rudraiah; Xi Zhang; Li Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

3.  An autoregulatory feedback loop between Mdm2 and SHP that fine tunes Mdm2 and SHP stability.

Authors:  Zhihong Yang; Li Wang
Journal:  FEBS Lett       Date:  2012-03-23       Impact factor: 4.124

4.  MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.

Authors:  Zhihong Yang; Hiroyuki Tsuchiya; Yuxia Zhang; M Elizabeth Hartnett; Li Wang
Journal:  J Biol Chem       Date:  2013-08-26       Impact factor: 5.157

5.  Cross-regulation of protein stability by p53 and nuclear receptor SHP.

Authors:  Zhihong Yang; Yuxia Zhang; Jongsook Kim Kemper; Li Wang
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

6.  A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening.

Authors:  Sang Jun Lee; Madhupriya Mahankali; Abdallah Bitar; Huafei Zou; Elizabeth Chao; Hung Nguyen; Jose Gonzalez; Dawna Caballero; Mitch Hull; Danling Wang; Peter G Schultz; Weijun Shen
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

7.  A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13.

Authors:  Zhihong Yang; Yuxia Zhang; Li Wang
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.